The drug, which goes by the brand name Nucynta, is already approved for acute pain.
Tapentadol is a centrally acting synthetic analgesic. This oral mu-opioid agonist is taken twice daily in adults when a continuous, around-the-clock analgesic is needed over an extended time period.
Related Articles on FDA Device Approvals:
Technological Changes Affecting Eye ASCs: Q&A With Larry Patterson of Eye Centers of Tennessee
French Diagnostics Company Receives FDA Approval for MRSA Test
FDA Approves Solesta to Treat Life-Altering Fecal Incontinence
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.